Evidence map›Paper›PMID 35433927›Full record

ArticleAnnals of translational medicine2022

An advanced non-small cell lung cancer patient with

Ronghua Yang, Dong Wang, Xia Li, Kaiping Mao, Jinglong Wang, Peng Li, Xiaoliang Shi, Shanshan Zhang, Yongjie Wang

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ronghua YangDepartment of Thoracic, The Affiliated Hospital of Qingdao University, Qingdao, China.
Dong WangDepartment of Thoracic, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xia LiDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Kaiping MaoDepartment of Thoracic, The Affiliated Hospital of Qingdao University, Qingdao, China.
Jinglong WangDepartment of Thoracic, The Affiliated Hospital of Qingdao University, Qingdao, China.
Peng LiDepartment of Thoracic, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xiaoliang ShiDepartment of Medicine, Shanghai OrigiMed Co., Ltd., Shanghai, China.
Shanshan ZhangDepartment of Medicine, Shanghai OrigiMed Co., Ltd., Shanghai, China.
Yongjie WangDepartment of Thoracic, The Affiliated Hospital of Qingdao University, Qingdao, China.
Qingdao University · CNAffiliated Hospital of Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with epidermal growth factor receptor ( Case Description: In this study, we reported the case of a 56-year-old NSCLC patient who harbored the mutations of EGFR L858R and KRAS G12D, with a high tumor mutational burden value and positive PD-L1 expression. Considering the Conclusions: Our results indicated that immunotherapy may be a potential choice in NSCLC with

Indexed as

case reportepidermal growth factor receptor (EGFR)immunotherapyNon-small cell lung cancer (NSCLC)programmed death-ligand 1 (PD-L1)

Identifiers

PMID35433927
PMCPMC9011273
OpenAlexW4224232964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.